Activity ex vivo of cytotoxic drugs in patient samples of peritoneal carcinomatosis with special focus on colorectal cancer

Table 3 Concentration ratios between IPC C_max and ex vivo IC₅₀ values

C_max ^†	IC₅₀	C_max	IC₅₀	C_max	IC₅₀	C_max	IC₅₀	C_max	IC₅₀	C_max
	CRC	/IC₅₀	Meso	/IC₅₀	PMP	/IC₅₀	App	/IC₅₀	Ova	/IC₅₀
	μM	CRC	μM	Meso	μM	PMP	μM	App	μM	Ova
Oxa [23]
573 μM^‡	31	18.5	12	47.7	29	19.9	35	16.4	15	38.2
Cis [24]
92 μM^‡	23	4.0	8	11.5	25	3.7	30	3.1	9	10.2
MMC [25]
30 μM^‡	20	1.5	5	6	16	1.9	19	1.6	8	3.7
Iri [17]
197 μM^‡	139	1.4	75	2.6	290	0.7	150	1.3	100	2.0
Dox [14]
17 μM^‡	2.8	6.1	0.9	19.1	2.0	8.6	2.3	7.5	1.2	14.3

^† Maximum concentration achieved at the beginning of the IPC treatment.
^‡ Dosage during HIPEC: oxa - 460 mg/m², cis - 50 mg/m², MMC - 35 mg/m², Iri – 350 mg/m², Dox – 15 mg/m².
Abbreviations: IPC intraperitoneal chemotherapy, CRC colorectal cancer, Meso mesothelioma, PMP pseudomyxoma peritonei, App appendix cancer, Ova ovarian cancer, Oxa oxaliplatin, Cis cisplatin, MMC mitomycin C, Iri irinotecan, Dox doxorubicin, N/A not available, HIPEC hyperthermic intraperitoneal chemotherapy.

ISSN: 1471-2407